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ABSTRACT 
Osteoporosis, a degenerative bone disorder, is one of the leading causes of morbidity in the 
elderly. Proper nutrition plays a role in the prevention and treatment of osteoporosis. Intake 
of calcium and Vitamin D are some of the most important nutritional factors, and 
supplementation remains the gold standard and first line of treatment for low bone mineral 
density and osteoporosis. Supplementation can prevent bone loss and reduce fracture risk. 
This work set about to produce, characterise and encapsulate for direct delivery to the bone 
various micro and nano sized calcium based mineral compounds which may be beneficial to 
bone health, using the precipitation method and biomimetic processes. 
Calcium phosphate mineral was produced and characterised, including hydroxyapatite (Hap), 
dicalcium phosphate dihydrate (DCPD), as well as multiphase and substituted calcium 
phosphates using biomimetic process. Standard simulated body Fluid (SBF) solution was 
modified, creating a high carbonate solution which better mimics the bone environment, and 
produces precipitates more similar to bone than traditional low carbonate SBF, as confirmed 
using Fourier Tansform Infrared Spectroscopy (FTIR) and X-Ray Diffraction (XRD). 
The use of liposomes as a delivery vesicle for the calcium mineral was evaluated usmg 
FTIR, XRD, Electron Dispersive Spectroscopy, Mass Spectrometry Transmission and 
Scanning Electron Microscopy, and X-Ray Mapping. The calcium mineral from aqueous 
solutions and prepared HAp and DCPD was incorporated into the liposome. 
Functional groups were synthesised based on a published structure used to target the bone 
marrow macrophage, and incorporation into liposomes was confitmed using Nuclear 
Magnetic Resonance Spectroscopy and FTIR. Preliminary cell culture studies showed no 
direct effect on osteoblast like Mg63 or Saos-2 cells or osteoclast resorption, measured by 
bone collagen release. 
Macrophage response was explored using U93 7 cell line. Expression of TNF-a and IL-1 , 
markers of inflammation, increased with liposome treatments compared to the negative control 
but decreased compared the positive control. The Mg63 cells given U937 supematants showed 
liposomes increased OPG production, but this was regardless of mineralisation. 
The calcium based mineral compounds were produced, characterised, successfully 
encapsulated using liposomes and functionalised to improve uptake at the bone site . This 
shows the potential to deliver calcium to the bone, however further work to inhibit 
inflammation and increase the calcium dose to elicit greater cell response is required before 
this approach can be developed as a treatment option. 
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